Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510727 | 0.75 | — | — | |
| SCHEMBL1287867 | 0.71 | LMNA (0.30) | — | |
| SCHEMBL12489483 | 0.69 | — | — | |
| SCHEMBL28437230 | 0.69 | TP53 (0.35) | — | |
| SCHEMBL7963281 | 0.68 | — | — | |
| SCHEMBL2989721 | 0.64 | KDM4E (0.38) | KDM4E | |
| SCHEMBL708336 | 0.64 | TP53 (0.30) | — | |
| SCHEMBL354742 | 0.64 | SLC22A6 (0.31) | — | |
| SCHEMBL3797120 | 0.61 | TP53 (0.36) | — | |
| Sulfuric Acid SCHEMBL11125847 | 0.60 | KDM4E (0.37) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618058-B2 | Blends containing proteases | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| CN-114635282-B | Preparation method of flexible electromagnetic shielding material based on two-dimensional titanium carbide and aramid fiber compounding | 江苏新视界先进功能纤维创新中心有限公司 | 2024-12-24 | — | — | CN | claimed |
| US-20240373862-A1 | ANTIMICROBIAL NANO-EMULSION | LABORATOIRE M2 (CA) | 2024-11-14 | — | — | US | claimed |
| CN-114235769-B | Blood cell staining method | 深圳市路美康尔医疗科技有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117585987-B | Tundish coating material and preparation method thereof | 河北国亮新材料股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117585987-A | Tundish coating material and preparation method thereof | 河北国亮新材料股份有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-114031533-B | Preparation method of high-content thiodicarb | 山东华阳农药化工集团有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-114031533-A | Preparation method of high-content thiodicarb | 山东华阳农药化工集团有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-102869392-A | Method for producing acellular dermal matrix, and acellular dermal matrix produced by same | CG BIO CO LTD | 2013-01-09 | — | — | CN | claimed |
| US-6451256-B1 | RECOMBINANT VIRUSES IN FROZEN OR LIQUID FORM, IN WHICH INFECTIOUS VIRUSES ARE PRESERVED IN AN AQUEOUS SOLUTION. THE RECOMBINANT VIRUS SUSPENSION COMPRISES AN AQUEOUS SUCROSE SOLUTION AT A CONCENTRATION FOR GENE THERAPY. | TRANSGENE S.A. (FR) | 2002-09-17 | — | — | US | claimed |
| US-5464516-A | Process for producing an electrophoresis separation layer | HYMO CORPORATION (JP) | 1995-11-07 | — | — | US | claimed |
| EP-0571066-A2 | Storage and calibration solution for multiparameter intravascular blood gas sensor device | PURITAN-BENNETT CORPORATION (US) | 1993-11-24 | — | — | EP | claimed |
| CN-122017230-A | Immunodiagnosis reagent promoter and preparation method thereof | 北京昂领科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250179481-A1 | COMPOSITIONS AND METHODS FOR TARGETING, EDITING, OR MODIFYING GENES | ARTISAN (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC | 2025-06-05 | — | — | US | disclosed |
| CN-119255824-A | Ligand-drug conjugates with improved pharmacokinetic and drug release profiles | 德比欧药物研究有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-114635282-B | Preparation method of flexible electromagnetic shielding material based on two-dimensional titanium carbide and aramid fiber compounding | 江苏新视界先进功能纤维创新中心有限公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-0189142-A2 | Arylalkoxyphenyl-allylic alcohols as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1986-07-30 | — | — | EP | disclosed |
| EP-0187989-A1 | Bis-imidazolinoamino derivatives as useful antiallergy compounds | USV PHARMACEUTICAL CORPORATION (US) | 1986-07-23 | — | — | EP | disclosed |
| EP-0037256-B1 | PROCESS FOR PRODUCING AN INSULIN | ELI LILLY AND COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
| US-4051232-A | SEROLOGIC TEST FOR SYSTEMIC CANDIDIASIS | SCHERING CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618058-B2 | Blends containing proteases | CTRL, CA2, CAPN2 | KDM4E 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.